LeMaitre Vascular, Inc. (LMAT) News
Filter LMAT News Items
LMAT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LMAT News Highlights
- LMAT's 30 day story count now stands at 10.
- Over the past 24 days, the trend for LMAT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BEAT, DAVE and NUVA are the most mentioned tickers in articles about LMAT.
Latest LMAT News From Around the Web
Below are the latest news stories about Lemaitre Vascular Inc that investors may wish to consider to help them evaluate LMAT as an investment opportunity.
LeMaitre Vascular's (LMAT) CEO George LeMaitre on Q4 2021 Results - Earnings Call TranscriptLeMaitre Vascular, Inc. (LMAT) Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET Company Participants JJ Pellegrino – Chief Financial Officer George LeMaitre – Chairman and Chief Executive Officer Dave Roberts – President Conference Call Participants Brooks O’Neil – Lake Street Scott Henry – Roth Capital Zachary Weiner... |
LeMaitre Vascular (LMAT) Misses Q4 Earnings and Revenue EstimatesLeMaitre (LMAT) delivered earnings and revenue surprises of -9.68% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
LeMaitre Q4 2021 Financial ResultsBURLINGTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2021 results, announced a $0.125/share quarterly dividend (+14%) and provided guidance. Q4 2021 Financial Results Sales of $39.5mm, +5% (+6% organic) vs. Q4 2020Op. income of $8.3mm, -13%Op. margin of 21%Net income of $6.2mm, -12%Earnings of $0.28 per diluted share, -18%Cash and investments +$2.9mm to $70.0mm Q4 2021 sales were driven by bovine gra |
NuVasive (NUVA) Q4 Earnings Lag EstimatesNuVasive (NUVA) delivered earnings and revenue surprises of -14.89% and 1.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out forLeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
LeMaitre Will Announce Fourth Quarter 2021 Earnings Results February 24, 2022BURLINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. |
LeMaitre to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBURLINGTON, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 16, 2022, at 10:30 AM ET. LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures |
Knowledge Leaders Capital, LLC Buys MaxLinear Inc, Broadcom Inc, Omnicell Inc, Sells Schwab U.S. ...Investment company Knowledge Leaders Capital, LLC (Current Portfolio) buys MaxLinear Inc, Broadcom Inc, Omnicell Inc, Amphenol Corp, NetApp Inc, sells Schwab U.S. |
Could The Market Be Wrong About LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Its Attractive Financial Prospects?With its stock down 20% over the past three months, it is easy to disregard LeMaitre Vascular (NASDAQ:LMAT). However... |
AHCO vs. LMAT: Which Stock Should Value Investors Buy Now?AHCO vs. LMAT: Which Stock Is the Better Value Option? |